Skip to main content

Cerevel Therapeutics Holdings, Inc.

CEREDelisted Aug 1, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001805387

Cerevel Therapeutics Holdings, Inc. was delisted on Aug 1, 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.42B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cerevel Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cerevel Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cerevel Therapeutics Holdings, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bain Capital Investors LLCDirector, 10% Owner0IndirectAug 5, 20240
Bain Capital Fund XII, LPDirector, 10% Owner0IndirectAug 5, 20240
BCPE Perception GP, LLCDirector, 10% Owner0IndirectAug 5, 20240
BC Perception Holdings, LPDirector, 10% Owner0IndirectAug 5, 20240
Bain Capital Partners XII, LLCDirector, 10% Owner0IndirectAug 5, 20240
Pfizer IncOther: Former 10% Owner0Aug 5, 20240
Patrick Deval LDirector0Aug 5, 20240
Riedel Norbert GDirector0Aug 5, 20240
Coles N AnthonyDirector0Aug 5, 20240
Dekkers Marijn EDirector0IndirectAug 5, 20240
Sulzberger GabrielleDirector0Aug 5, 20240
Renaud Ronald C JRPresident & CEO0IndirectAug 5, 20240
Giordano Douglas E.Director0Aug 5, 20240
Gordon Christopher RDirector, 10% Owner0IndirectAug 5, 20240
Mckernan RuthDirector0Aug 5, 20240
DiPietro KennethChief Human Resources Officer0Aug 5, 20240
Koppel AdamDirector, 10% Owner0IndirectAug 5, 20240
Burgess Paul D.See Remarks0Aug 5, 20240
Akamine ScottChief Legal Officer0Aug 5, 20240
ALTSCHULLER SusanChief Financial Officer0Aug 5, 20240
Sanchez RamiroChief Medical Officer0Aug 5, 20240
Renger JohnChief Scientific Officer0Aug 5, 20240
Bodenrader MarkSee Remarks0Aug 5, 20240
Tregoning KathleenSee Remarks0Aug 5, 20240
Edelman JosephDirector0IndirectFeb 21, 20240
Perceptive Advisors LLCDirector0IndirectFeb 21, 20240
Perceptive Life Sciences Master Fund LtdDirector0IndirectFeb 21, 20240
Ceesay AbrahamPresident0Feb 8, 20230
PF Equity Holdings 1 B.V.10% Owner0Apr 4, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 9, 2021 (view filing)6:39 PM ETJul 72 daysEdelman Joseph and 2 othersDirectorPPurchase+200.0K$25.00+$5.00M+4.3%4.84M after
Aug 25, 2021 (view filing)7:14 PM ETAug 23-252 daysEdelman Joseph and 2 othersDirectorPPurchase+175.6K$27.53+$4.83M+3.6%5.02M after3 lots
Aug 31, 2021 (view filing)2:15 PM ETAug 265 daysLateEdelman Joseph and 2 othersDirectorPPurchase+68.0K$30.23+$2.06M+1.4%5.09M after
Nov 15, 2021 (view filing)Nov 105 daysRenger JohnChief Scientific OfficerSSale−55.0K$39.86−$2.19M−100.0%0 after5 lots
Dec 17, 2021 (view filing)Dec 15-172 daysRenger JohnChief Scientific OfficerSSale−37.7K$30.86−$1.16M−95.0%1.98K after3 lots
Dec 23, 2021 (view filing)Dec 212 daysRenger JohnChief Scientific OfficerSSale−7.30K$32.50−$237.3K−78.7%1.98K after
Dec 28, 2021 (view filing)Dec 23-275 daysRenger JohnChief Scientific OfficerSSale−10.0K$35.00−$350.0K−83.5%1.98K after2 lots
Feb 11, 2022 (view filing)Feb 92 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−92.7%1.98K after
Mar 4, 2022 (view filing)Mar 22 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−92.7%1.98K after
Mar 11, 2022 (view filing)Mar 92 daysRenger JohnChief Scientific OfficerSSale−30.0K$33.33−$1.00M−93.8%1.98K after2 lots
Mar 18, 2022 (view filing)Mar 16-182 daysRenger JohnChief Scientific OfficerSSale−45.0K$31.11−$1.40M−95.8%1.98K after2 lots
Mar 31, 2022 (view filing)Mar 292 daysRenger JohnChief Scientific OfficerSSale−10.0K$35.00−$350.0K−83.5%1.98K after
Apr 15, 2022 (view filing)Apr 132 daysRenger JohnChief Scientific OfficerSSale−45.0K$34.65−$1.56M−95.8%1.98K after
Jul 7, 2022 (view filing)Jul 5-62 daysRenger JohnChief Scientific OfficerSSale−26.1K$30.11−$785.9K−90.6%2.70K after2 lots
Jul 22, 2022 (view filing)Jul 202 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−90.2%2.70K after
Aug 9, 2022 (view filing)Aug 5-84 daysCeesay AbrahamPresidentSSale−57.6K$34.54−$1.99M−100.0%0 after3 lots
Aug 9, 2022 (view filing)Aug 81 dayAkamine ScottChief Legal OfficerSSale−10.0K$40.00−$400.0K−100.0%0 after
Aug 9, 2022 (view filing)Aug 5-84 daysRenger JohnChief Scientific OfficerSSale−30.0K$34.25−$1.03M−91.7%2.70K after2 lots
Aug 12, 2022 (view filing)Aug 102 daysRenger JohnChief Scientific OfficerSSale−55.0K$40.50−$2.23M−95.3%2.70K after2 lots
Aug 17, 2022 (view filing)Aug 152 daysCeesay AbrahamPresidentSSale−9.61K$34.12−$327.8K−100.0%0 after
Aug 18, 2022 (view filing)5:10 PM ETAug 162 daysEdelman Joseph and 2 othersDirectorPPurchase+1.43M$35.00+$49.9M+28.0%6.51M after
Aug 18, 2022 (view filing)5:10 PM ETAug 162 daysEdelman Joseph and 2 othersDirectorPPurchase+2.16M–––DerivativePrice outlier
Aug 24, 2022 (view filing)Aug 222 daysCeesay AbrahamPresidentSSale−9.61K$32.50−$312.2K−100.0%0 after
Sep 12, 2022 (view filing)Sep 84 daysCeesay AbrahamPresidentSSale−19.2K$32.50−$624.3K−100.0%0 after
Sep 14, 2022 (view filing)Sep 122 daysPatrick Deval LDirectorSSale−47.7K$30.78−$1.47M−100.0%0 after
Oct 6, 2022 (view filing)Oct 42 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−90.2%2.70K after
Nov 3, 2022 (view filing)Nov 12 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−90.2%2.70K after
Dec 13, 2022 (view filing)Dec 94 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$26.67−$1.33M−94.9%2.70K after2 lots
Jan 6, 2023 (view filing)Jan 51 dayColes N AnthonyCEO and ChairpersonSSale−50.0K$29.94−$1.50M−94.9%2.70K after2 lots
Feb 8, 2023 (view filing)Feb 71 dayColes N AnthonyCEO and ChairpersonSSale−50.0K$33.12−$1.66M−94.9%2.70K after2 lots
Mar 6, 2023 (view filing)Mar 2-34 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$27.11−$1.36M−94.9%2.70K after2 lots
Apr 13, 2023 (view filing)Apr 112 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$25.06−$1.25M−94.9%2.70K after10b5-1
May 8, 2023 (view filing)May 44 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$31.47−$1.57M−94.9%2.70K after3 lots10b5-1
Jun 5, 2023 (view filing)Jun 23 daysBodenrader MarkSee RemarksSSale−1.90K$32.95−$62.4K−25.5%5.52K after10b5-1
Jun 5, 2023 (view filing)Jun 14 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$32.60−$1.63M−94.9%2.70K after10b5-1
Jun 20, 2023 (view filing)Jun 155 daysDekkers Marijn EDirectorSSale−200.0K$34.43−$6.89M−33.2%402.3K after
Jul 13, 2023 (view filing)Jul 112 daysColes N AnthonyDirectorSSale−50.0K$30.03−$1.50M−94.9%2.70K after10b5-1
Aug 7, 2023 (view filing)Aug 43 daysBurgess Paul D.See RemarksPPurchase+21.9K$22.93+$501.7KNew position21.9K after
Aug 7, 2023 (view filing)Aug 34 daysRenaud Ronald C JRPresident & CEOPPurchase+83.9K$23.96+$2.01MNew position83.9K after
Sep 8, 2023 (view filing)Sep 71 dayColes N AnthonyDirectorSSale−50.0K$24.07−$1.20M−94.9%2.70K after
Oct 17, 2023 (view filing)4:53 PM ETOct 161 dayEdelman Joseph and 2 othersDirectorPPurchase+876.8K$22.81+$20.0M+8.8%10.8M after
Oct 18, 2023 (view filing)Oct 162 daysGordon Christopher RDirector, 10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M after
Oct 18, 2023 (view filing)Oct 162 daysKoppel AdamDirector, 10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M afterDuplicate filing
Oct 18, 2023 (view filing)4:30 PM ETOct 162 daysBain Capital Investors LLC and 4 others10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M afterDuplicate filing
Nov 3, 2023 (view filing)Nov 12 daysPatrick Deval LDirectorSSale−30.1K$25.00−$753.3K−90.2%3.28K after
Nov 6, 2023 (view filing)Nov 2-34 daysColes N AnthonyDirectorSSale−100.0K$25.34−$2.53M−97.4%2.70K after2 lots
Nov 9, 2023 (view filing)Nov 7-82 daysColes N AnthonyDirectorSSale−27.2K$25.02−$680.0K−91.0%2.70K after2 lots
Nov 16, 2023 (view filing)Nov 142 daysColes N AnthonyDirectorSSale−22.8K$25.13−$573.6K−89.4%2.70K after
Dec 7, 2023 (view filing)Dec 5-72 daysAkamine ScottChief Legal OfficerSSale−17.5K$38.64−$676.2K−97.2%513 after2 lots10b5-1
Dec 11, 2023 (view filing)Dec 74 daysSanchez RamiroChief Medical OfficerSSale−10.0K$41.37−$413.7K−100.0%0 after10b5-1